PeriodontitisBack

PeriodontitisBack

Patients Are Counting on You to Take Action

Scaling and Root Planing (SRP) Alone May Not Achieve and Sustain a Healthier Balance of Bacteria1

With treatment by mechanical procedures alone, baseline levels of bacteria may return after just a few days.2

Since periodontitis manifests at both the microbial and clinical levels,2,3
a treatment plan that addresses both may be appropriate.

The goals of periodontal therapy are to:4

  • Attain periodontal health
  • Retain the dentition

Achieving these goals could reflect improvement in the following:5

  • Pocket depth (PD) reduction
  • Unchanging or improving attachment and bone levels

Find out how adding ARESTIN® at the time of SRP may improve clinical outcomes for periodontal patients.

REFERENCES: 1. Goodson JM, Gunsolley JC, Grossi SG, et al. Minocycline HCI microspheres reduce red-complex bacteria in periodontal disease therapy. J Periodontol. 2007;78(8):1568-1579. 2. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 2002;28:12-55. 3. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL. Microbial complexes in subgingival plaque. J Clin Periodontol. 1998;25:134-144. 4. Greenstein G. Clinical versus statistical significance as they relate to the efficacy of periodontal therapy. JADA. 2003;134:583-591. 5. Armitage GC. Periodontal diseases: diagnosis. Ann Periodontol. 1996;1(1):37-215. 6. Data on file. OraPharma, Inc. Horsham, PA; 2011. 

87% of patients surveyed feel it’s important that you
take appropriate action to fight the infection.6  


Learn about what may
help your patients.

INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please read the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

MyArestinTM is a trademark and ARESTIN® is a registered trademark of OraPharma, Inc.

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Manufactured for OraPharma, Inc. ©OraPharma, Inc. 2013   A-1373-12   01/13